These are strategic decisions that either align with or work against the broader healthspan objectives of the combined approach

Here are some key points about Zepbound: Composition and function: Contains tirzepatide, a compound also present in the diabetes medication Mounjaro Includes semaglutide and an additional hormone, GIP, to increase insulin secretion further and decrease appetite Acts as a dual agonist, activating both GLP-1 and GIP receptors Dosage and administration: Administered as a 2.5 mg weekly injection for the first month, then potentially increased to 5 mg weekly Dosage can be adjusted, with a maximum of 15 mg per week depending on individual needs and doctors guidance Indications and usage: Approved for use in adults 18 years and older with a body mass index (BMI) of 30 or higher (obese), or a BMI of 27 or higher (overweight) with at least one weight-related health condition To be used alongside a reduced-calorie diet and increased physical activity for optimal results Continuous usage may be necessary for maintaining weight loss, and patients should consider the benefits in relation to potential side effects and costs The efficacy of Zepbound in aiding weight loss is notable, with clinical trials showcasing significant results

From there, the researchers tested 100 peptides they knew or suspected could affect the brains hunger drive (including GLP-1 for comparison)
They can reduce appetite on their own, but the best results require structureespecially protein intake and strength training to preserve lean mass
In the context of SUD, such mechanisms could plausibly reduce craving and compulsive drug-seeking, aligning with preclinical work showing attenuation of substance-related reinforcement and with emerging clinical data suggesting reduced alcohol-related outcomes among GLP-1RA users (18, 35)